Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CVT-E002

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND Chronic lymphocytic leukemia (CLL) patients are at high risk for acute respiratory illness (ARI). OBJECTIVE We… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
2012
2012
Cells belonging to the innate immune system are referred to as natural killer (NK) cells. We recently demonstrated that normal… Expand
2011
2011
Objectives  There is interest in developing new compounds to enhance the immune response to airway virus infections. CVT‐E002 is… Expand
2011
2011
Background Human peripheral blood neutrophils contribute to the first line of defence in the immune system and are critical for… Expand
2009
2009
The present study evaluated the dose-related effects of CVT-E002, a proprietary extract of Panax quinquefolius (CV Technologies… Expand
2008
2008
CVT-E002 (sold commercially as COLD-fX) is a patented, polysaccharide-rich extract of North American ginseng (Panax quinquefolium… Expand
Highly Cited
2006
Highly Cited
2006
BACKGROUND COLD-fX (CVT-E002), a proprietary extract of the roots of North American ginseng (Panax quinquefolium), rich in poly… Expand
Highly Cited
2004
Highly Cited
2004
Objectives: To compare a proprietary extract of American ginseng, CVT‐E002, with placebo in preventing acute respiratory illness… Expand
Highly Cited
2004
Highly Cited
2004
A patented aqueous extract from North American ginseng (Panax quinquefolium), containing mainly oligosaccharides and… Expand
Highly Cited
2001
Highly Cited
2001
The activity of CVT‐E002, an aqueous extract containing mainly oligosaccharides and polysaccharides from North American ginseng… Expand